Company intelligence / Profile preview

Symbiomics

Florianópolis, Santa Catarina, Brazil

Ownership: Private
Development stage: Other

Overview

Symbiomics has catalogued thousands of robust microbes using sequencing, machine learning, and genome editing, and is developing high-performance biologicals for crop nutrition, biocontrol, and resilience. No clinical trial data as company is agriculture focused, but has active collaborations and programs in development with new products expected to accelerate commercialization via strategic partnerships.[1][2][4]

Therapeutic areas: OtherInfectious Diseases
Modalities: Microbial therapyLive biotherapeutic product therapy
Industry: Agriculture & AgTech

Partnerships

Corteva

Beyond the preview

Go deeper on Symbiomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symbiomics.

Explore the full profile